Role of Clinical-Demographic Data in Survival Rates of Advanced Laryngeal Cancer
Abstract
:1. Introduction
2. Material and Methods
2.1. Patients
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nocini, R.; Molteni, G.; Mattiuzzi, C.; Lippi, G. Updates on larynx cancer epidemiology. Chin J. Cancer Res. 2020, 32, 18–25. [Google Scholar] [CrossRef] [PubMed]
- Allegra, E.; La Mantia, I.; Bianco, M.R.; Drago, G.D.; Le Fosse, M.C.; Azzolina, A.; Grillo, C.; Saita, V. Verbal performance of total laryngectomized patients rehabilitated with esophageal speech and tracheoesophageal speech: Impacts on patient quality of life. Psychol. Res. Behav. Manag. 2019, 12, 675–681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garozzo, A.; Allegra, E.; La Boria, A.; Lombardo, N. Modified supracricoid laryngectomy. Otolaryngol. Head Neck Surg. 2010, 142, 137–139. [Google Scholar] [CrossRef] [PubMed]
- de Vincentiis, M.; De Virgilio, A.; Bussu, F.; Gallus, R.; Gallo, A.; Bastanza, G.; Parrilla, C.; Greco, A.; Galli, J.; Turchetta, R.; et al. Oncologic results of the surgical salvage of recurrent laryngeal squamous cell carcinoma in a multicentric retrospective series: Emerging role of supracricoid partial laryngectomy. Head Neck. 2015, 37, 84–91. [Google Scholar] [CrossRef] [PubMed]
- Kulhánová, I.; Forman, D.; Vignat, J.; Espina, C.; Brenner, H.; Storm, H.H.; Bauld, L.; Soerjomataram, I. Tobacco-related cancers in Europe: The scale of the epidemic in 2018. Eur. J. Cancer 2020, 139, 27–36. [Google Scholar] [CrossRef] [PubMed]
- Pulte, D.; Brenner, H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. Oncologist 2010, 15, 994–1001. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gatta, G.; Botta, L.; Sánchez, M.J.; Anderson, L.A.; Pierannunzio, D.; Licitra, L.; Eurocare Working Group. Prognoses and im-provement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur. J. Cancer. 2015, 51, 2130–2143. [Google Scholar] [CrossRef] [PubMed]
- Dahm, V.; Haitel, A.; Kaider, A.; Stanisz, I.; Beer, A.; Lill, C. Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas. Eur. Arch. Oto-Rhino Laryngol. 2018, 275, 1837–1843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beynon, R.A.; Lang, S.; Schimansky, S.; Penfold, C.M.; Waylen, A.; Thomas, S.J.; Pawlita, M.; Waterboer, T.; Martin, R.M.; May, M.; et al. Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: Results from head and neck 5000, a prospective observational cohort of people with head and neck cancer. Int. J. Cancer 2018, 143, 1114–1127. [Google Scholar] [CrossRef] [PubMed]
- Innocentini, L.M.A.R.; Teixeira, A.H.; Casemiro, L.A.; Andrade, M.C.; Ferrari, T.C.; Ricz, H.M.A.; De Macedo, L.D. Laryngeal Cancer Attributable Factors and the Influence on Survival Rates: A Single Brazilian Institution Experience. Int. Arch. Otorhinolaryngol. 2019, 23, e299–e304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharp, L.; McDevitt, J.; Carsin, A.E.; Brown, C.; Comber, H. Smoking at diagnosis is an independent prognostic factor for can-cer-specific survival in head and neck cancer: Findings from a large, population-based study. Cancer Epidemiol. Prev. Biomark. 2014, 23, 2579–2590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giraldi, L.; Leoncini, E.; Pastorino, R.; Wünsch-Filho, V.; De Carvalho, M.; Lopez, R.; Cadoni, G.; Arzani, D.; Petrelli, L.; Matsuo, K.; et al. Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: A pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Ann. Oncol. 2017, 28, 2843–2851. [Google Scholar] [CrossRef] [PubMed]
- Pan, Y.; Hong, Y.; Liang, Z.; Zhuang, W. Survival analysis of distant metastasis of laryngeal carcinoma: Analysis based on SEER database. Eur. Arch. Oto Rhino Laryngol. 2019, 276, 193–201. [Google Scholar] [CrossRef] [PubMed]
- Allegra, E.; Garozzo, A.; Lombardo, N.; De Clemente, M.; Carey, T.E. Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. Acta Otorhinolaryngol. Ital. 2006, 26, 185–190. [Google Scholar] [PubMed]
- Allegra, E.; Trapasso, S. Cancer stem cells in head and neck cancer. Onco Targets Ther. 2012, 5, 375–383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dylawerska, A.; Barczak, W.; Wegner, A.; Golusinski, W.; Suchorska, W.M. Association of DNA repair genes polymorphisms and mutations with increased risk of head and neck cancer: A review. Med. Oncol. 2017, 34, 197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Data | Patients n.77 |
---|---|
AGE | |
Mean (years) ± SD | 66.0 ± 9.7 SD |
Follow-up | |
Mean ± SD (months) | 76.0 ± 43.3 SD |
Family history | |
No | 54 |
Yes | 23 |
Smoke habit | |
No/≤20 cig/day | 36 |
>20 cig/day | 41 |
Alcohol use | |
≤500 mL/day | 34 |
>500 mL/day | 43 |
Grading | |
1 | 5 |
2 | 42 |
3 | 30 |
Subsite | |
Supraglottic | 13 |
Transglottic | 23 |
Glottic | 31 |
pT STAGE | |
2 | 21 |
3 | 35 |
4 | 11 |
pN STAGE | |
N0 | 39 |
N+ | 38 |
Neck Dissection | |
No | 11 |
Yes | 66 |
Adjuvant therapy | |
No | 39 |
Yes | 38 |
Variable | b | SE | Wald | p | Exp(b) | 95% CI of Exp(b) |
---|---|---|---|---|---|---|
Age | −0.13 | 0.44 | 0.09 | 0.75 | 0.87 | 0.36 to 2.07 |
Family_History | −0.35 | 0.53 | 0.43 | 0.50 | 0.70 | 0.24 to 2.01 |
Alcohol | −0.70 | 0.45 | 2.41 | 0.12 | 0.49 | 0.20 to 1.20 |
Smoke | 1.29 | 0.44 | 7.32 | 0.00 | 3.33 | 1.39 to 7.98 |
Grading | 0.03 | 0.24 | 0.01 | 0.90 | 1.03 | 0.63 to 1.68 |
Subsite | −0.09 | 0.47 | 0.04 | 0.83 | 0.90 | 0.36 to 2.28 |
Stage | −0.24 | 0.54 | 0.20 | 0.64 | 0.78 | 0.26 to 2.27 |
pT_stage | 0.25 | 0.32 | 0.60 | 0.43 | 1.29 | 0.67 to 2.45 |
pN_stage | −0.00 | 0.46 | 0.00 | 0.99 | 0.99 | 0.40 to 2.47 |
Adjuvant_therapy | 0.51 | 0.40 | 1.58 | 0.20 | 1.67 | 0.75 to 3.73 |
Risk Factors | b | SE | Wald | p | Exp(b) | 95%CI of Exp(b) |
---|---|---|---|---|---|---|
Age | −0.37 | 0.45 | 0.66 | 0.41 | 0.68 | 0.27 to 1.69 |
Family_History | −0.12 | 0.55 | 0.04 | 0.82 | 0.88 | 0.29 to 2.63 |
Alcohol | −0.85 | 0.46 | 3.32 | 0.06 | 0.42 | 0.17 to 1.06 |
Smoke | 0.83 | 0.45 | 3.33 | 0.06 | 2.29 | 0.94 to 5.62 |
Grading | −0.10 | 0.25 | 0.15 | 0.69 | 0.90 | 0.54 to 1.48 |
Subsite | −0.14 | 0.47 | 0.09 | 0.75 | 0.86 | 0.34 to 2.18 |
Stage | −0.43 | 0.54 | 0.64 | 0.42 | 0.64 | 0.22 to 1.87 |
pT_stage | 0.21 | 0.32 | 0.43 | 0.51 | 1.23 | 0.65 to 2.34 |
pN_stage | 0.54 | 0.47 | 1.31 | 0.25 | 1.71 | 0.68 to 4.33 |
Adjuvant_therapy | 0.62 | 0.42 | 2.16 | 0.14 | 1.86 | 0.81 to 4.26 |
Covariate | b | SE | Wald | p | Exp(b) | 95% CI of Exp(b) |
---|---|---|---|---|---|---|
Age | 0.08 | 0.47 | 0.029 | 0.86 | 1.08 | 0.42 to 2.76 |
Family_History | −0.25 | 0.62 | 0.16 | 0.68 | 0.77 | 0.22 to 2.66 |
Alcohol | −0.67 | 0.47 | 1.97 | 0.15 | 0.50 | 0.19 to 1.30 |
Smoke | 1.11 | 0.50 | 4.94 | 0.02 | 3.05 | 1.14 to 8.16 |
Grading | −0.31 | 0.25 | 1.56 | 0.21 | 0.72 | 0.44 to 1.19 |
Subsite | −0.05 | 0.51 | 0.01 | 0.91 | 0.94 | 0.34 to 2.60 |
Stage | −0.21 | 0.57 | 0.13 | 0.70 | 0.80 | 0.26 to 2.47 |
pT_stage | 0.30 | 0.34 | 0.79 | 0.37 | 1.35 | 0.69 to 2.67 |
pN_stage | 0.48 | 0.51 | 0.90 | 0.34 | 1.62 | 0.59 to 4.44 |
Adjuvant_therapy | 0.81 | 0.45 | 3.19 | 0.07 | 2.25 | 0.92 to 5.50 |
Data | Smoke Habit No ≤ 20 cig/day | Smoke Habit > 20 cig/day | p Value |
---|---|---|---|
AGE | |||
Mean (years) | 65.2 ± 9.6 SD | 65.2 ± 9.4 SD | 0.99 |
Follow-up | |||
mean ± SD(months) | 90.9 ± 34.6 SD | 62.9 ± 46.3 SD | 0.003 |
Family history | |||
No | 23 | 31 | |
Yes | 13 | 10 | 0.32 |
Alcohol use | |||
No/<500 mL/day | 18 | 16 | |
>500 mL/day | 18 | 25 | 0.36 |
Grading | |||
1 | 2 | 3 | |
2 | 21 | 21 | |
3 | 13 | 17 | 0.07 |
Subsite | |||
Supraglottic | 9 | 14 | |
Transglottic | 12 | 11 | |
Glottic | 15 | 16 | 0.65 |
pT STAGE | |||
2 | 10 | 11 | |
3 | 17 | 18 | |
4 | 9 | 12 | 0.91 |
pN STAGE | |||
N0 | 22 | 17 | |
N+ | 14 | 24 | 0.11 |
Neck Dissection | |||
No | 9 | 5 | |
Yes | 27 | 36 | 0.23 |
Adjuvant therapy | |||
No | 16 | 23 | |
Yes | 20 | 18 | 0.36 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Allegra, E.; Bianco, M.R.; Ralli, M.; Greco, A.; Angeletti, D.; de Vincentiis, M. Role of Clinical-Demographic Data in Survival Rates of Advanced Laryngeal Cancer. Medicina 2021, 57, 267. https://doi.org/10.3390/medicina57030267
Allegra E, Bianco MR, Ralli M, Greco A, Angeletti D, de Vincentiis M. Role of Clinical-Demographic Data in Survival Rates of Advanced Laryngeal Cancer. Medicina. 2021; 57(3):267. https://doi.org/10.3390/medicina57030267
Chicago/Turabian StyleAllegra, Eugenia, Maria Rita Bianco, Massimo Ralli, Antonio Greco, Diletta Angeletti, and Marco de Vincentiis. 2021. "Role of Clinical-Demographic Data in Survival Rates of Advanced Laryngeal Cancer" Medicina 57, no. 3: 267. https://doi.org/10.3390/medicina57030267